Learning experience
2007.09.-2011.06. Bachelor's degree in Biological Sciences, School of Life Sciences, Sun Yat-sen University

2011.09.-2016.06. Doctoral degree (master's degree) Microbiology, Sun Yat-sen University, Sun Yat-sen Medical College

Work experience
2016.09.-2020.01. Postdoctoral Mobile workstation Immunology Major, Sun Yat-sen Medical College, Sun Yat-sen University

2020.02.-2023.04. Distinguished Full Researcher, Sun Yat-sen University, Sun Yat-sen Medical College

2023.05.- Associate Professor, Sun Yat-sen University, Sun Yat-sen Medical College

Personal profile
Dr. Bingfeng Liu graduated from the School of Life Sciences, Sun Yat-sen University and received his Ph.D. degree in Microbiology from the Sun Yat-sen School of Medicine, Sun Yat-sen University in 2016. From 2016 to 2023, he worked as a postdoctoral fellow and full-time researcher in Zhongshan School of Medicine, Sun Yat-sen University, and won the title of Outstanding Postdoctoral Fellow of Sun Yat-sen University in 2017. He has been an associate professor at Sun Yat-sen University since 2023.

He has been engaged in research in the field of molecular virology and immunology for a long time, and has made many important achievements in the elimination of HIV viral reservoir by therapeutic T cell immunotherapy, and originally developed bNAb-CAR T immune cell therapy targeting HIV viral reservoir, and applied for and won a number of national and PCT patents. The clinical study of bNAb-CAR-T was successfully carried out to clear the reservoir of latent infection of the virus, which has important guiding significance for the functional cure of AIDS. Published as first or corresponding author in the Journal of Clinical Investigation, Nature Communications, Signal Transduct Target Ther, mBio, Journal of Clinical Investigation Virology, Journal of Immunology, Frontiers in Immunology, Current Opinion in Virology, Cellular & Molecular Immunology has published several important papers. He has presided over a number of research projects, including the National Natural Science Foundation, the "13th Five-Year Plan" major special project on infectious diseases, the Guangdong Natural Science Foundation project, and the China Postdoctoral Science Foundation project.

The first author or corresponding author publishes the article
1.Zhang, Yiwen#;  Li, Rong#;  Li, Yuzhuang#;  Yang, Hong;  Zhou, Liqiong;  Yuan, Jing;  Pan, Ting;  Liu, Bingfeng*;  Zhang, Hui*;  He, Yaqing*;  Antibody response and cross-neutralization after Omicron BA.2 infection., Signal Transduction and Targeted Therapy, 2023

2.Zhang, Wanying#;  Zhou, Mo;  Chen, Cancan;  Wu, Shiyu;  Wang, Lilin;  Xia, Baijin;  Liu, Jun;  Ma, Xiancai;  Pan, Ting;  Zhang, Hui;  Li, Linghua;  Liu, Bingfeng*;  Identification of CD98 as a Novel Biomarker for HIV-1 Permissiveness and Latent Infection., mBio, 2022.

3.Liu, Bingfeng#;  Zhang, Wanying;  Xia, Baijin;  Jing, Shuliang;  Du, Yingying;  Zou, Fan;  Li, Rong;  Lu, Lijuan;  Chen, Shaozhen;  Li, Yonghong;  Hu, Qifei;  Lin, Yingtong;  Zhang, Yiwen;  He, Zhangping;  Zhang, Xu;  Chen, Xiejie;  Peng, Tao;  Tang, Xiaoping;  Cai, Weiping;  Pan, Ting*;  Li, Linghua*;  Zhang, Hui*;  Broadly neutralizing antibody-derived CAR-T cells reduce viral reservoir in HIV-1-infected individuals.,  Journal of Clinical Investigation, 2021.

4.Liu, Bingfeng#;  Shi, Yaling#;  Zhang, Wanying#;  Li, Rong#;  He, Zhangping;  Yang, Xiaofan;  Pan, Yuejun;  Deng, Xilong;  Tan, Mingkai;  Zhao, Lingzhai;  Zou, Fan;  Zhang, Yiwen;  Pan, Ting;  Zhang, Junsong;  Zhang, Xu;  Xiao, Fei;  Li, Fang*;  Deng, Kai*;  Zhang, Hui*;  Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.,  Cellular and Molecular Immunology, 2020, 17(10): 1098-1100.

5.Zou, Fan#;  Lu, Lijuan#;  Liu, Jun;  Xia, Baijin;  Zhang, Wanying;  Hu, Qifei;  Liu, Weiwei;  Zhang, Yiwen;  Lin, Yingtong;  Jing, Shuliang;  Huang, Mei;  Huang, Bifen;  Liu, Bingfeng*;  Zhang, Hui*;  Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56.,  Nature Communications, 2019, 10(1): 4109.

6.Liu, Bingfeng#;  Zhang, Xu#;  Zhang, Wanying;  Wu, Liyang;  Jing, Shuliang;  Liu, Weiwei;  Xia, Baijin;  Zou, Fan;  Lu, Lijuan;  Ma, Xiancai;  He, Dalian;  Hu, Qifei;  Zhang, Yiwen;  Deng, Kai;  Cai, Weiping;  Tang, Xiaoping;  Peng, Tao;  Zhang, Hui*;  Li, Linghua*;  Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef-AP-1 Complex Formation:  A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells., Frontiers in Immunology, 2019, 10: 2151.

7.Liu, Bingfeng#;  Zhang, Wanying;  Zhang, Hui*;  Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir., Current Opinion in Virology,  2019, 38: 21-30.

8.Zhang, Yiwen#;  Liu, Weiwei;  Chen, Yingshi;  Liu, Jun;  Wu, Kang;  Su, Lishi;  Zhang, Wanying;  Jiang, Yawen;  Zhang, Xu;  Zhang, Yijun;  Liu, Chao;  Tao, Liang;  Liu, Bingfeng*;  Zhang, Hui*;  A Cellular MicroRNA Facilitates Regulatory T Lymphocyte Development by Targeting the FOXP3 Promoter TATA-Box Motif.,  The Journal of Immunology, 2018, 200(3): 1053-1063.

9.Liu, Bingfeng#;  Zou, Fan#;  Lu, Lijuan;  Chen, Cancan;  He, Dalian;  Zhang, Xu;  Tang, Xiaoping;  Liu, Chao;  Li, Linghua*;  Zhang, Hui*;  Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and  Effectively Eradicate Virus Reactivated from Latency in CD4( ) T Lymphocytes Isolated from HIV-1-Infected Individuals  Receiving Suppressive Combined Antiretroviral Therapy, Journal of Virology, 2016, 90(21): 9712-9724.

10.Geng, Guannan#;  Liu, Bingfeng;  Chen, Cancan;  Wu, Kang;  Liu, Jun;  Zhang, Yijun;  Pan, Ting;  Li, Jun;  Yin, Yue;  Zhang, Junsong;  Huang, Feng;  Yu, Fei;  Chen, Jingliang;  Ma, Xiancai;  Zhou, Jie;  Kuang, Ersheng;  Liu, Chao;  Cai, Weiping;  Zhang, Hui*;  Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency,  Molecular Therapy, 2016, 24(9): 1528-1537.

Lead a science project
National Natural Science Foundation of China, Youth Science Foundation Project: Study on the clearance of reactivated HIV-1 latent infection reservoir by CAR T cells co-expressing inhibitory receptor shRNA
The Key project of the 13th Five-Year Plan for Infectious Diseases, Identification of markers for accurate Diagnosis and Treatment of AIDS subproject 3 - Identification of novel HIV-1 latent infected cell subsets in lymph node tissues of patients with different disease processes
Natural Science Foundation of Guangdong Province, Surface project: Study on the long-term survival of CAR-T cells and elimination of HIV-1 virus reservoir by specific knockout of GSK3
China Postdoctoral Science Foundation, Surface project: CAR T cells specifically clear reactivated HIV-1 latent infected cells

patent
Zhang Hui; Liu Bingfeng; Zou Fan; A VC#CAR molecule and its application in clearing HIV# 1-infected cells, 2016-08-10, China, CN201610652995.9.
VC-CAR molecule and use thereof in removing hiv-1 infected cell, United States Patent, Patent No: US 10,633,432 B2